Abstract
Objective: Multiple RCTs show increased overall survival in women with advanced ovarian cancer treated with intraperitoneal (IP) cisplatin chemotherapy compared to intravenous; however, uptake is poor because of toxicity concerns. Substitution of IP carboplatin as a viable therapeutic option was analyzed for outcomes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
